BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Breaking: STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, & more
Breaking: STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, & more

Breaking: STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, & more

April 24, 2016 By Cade Hildreth (CEO) Leave a Comment

This was a major week in the stem cell sector, with significant announcements released by STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, and more. The FDA also released significant news pertaining to a public hearing that will  address the regulation of stem cells within the United States.

Discover class-defining bioproduction tools.

Check it out and let us know what you think!

STEMCELL Technologies Partners with IMBA to Commercialize Brain Organoids (‘Mini Brains’) for Researchers

bitbio

STEMCELL Technologies announced that it has partnered with the Institute of Molecular Biotechnology (IMBA) in Vienna, Austria, to develop products for cerebral organoid culture. Founded in 1993 and headquartered in Vancouver, STEMCELL Technologies is a diversified provider of stem cell research products. The company is known for utilizing strategic alliances to grow its dominance within the stem cell field, with current partnerships including licensing deals with the Wisconsin Alumni Research Foundation (WARF), iPS Academia Japan Inc., Salk Institute for Biological Sciences, and more.

Israel Continues to Cultivate Stem Cell Innovation as Cellect and Accellta Enter Into Collaborative Agreement

Pluristyx

Cellect Biomed Ltd. and Accellta announced that they have signed an agreement to evaluate Cellect’s apoptotic induction based technology in combination with Accellta’s stem cell culturing technologies. Cellect Biomed Ltd. is headquartered in Tel Aviv, while Accellta is headquartered in Haifa, Israel. Accellta can quickly, efficiently, and cost-effectively grow massive quantities of clinical grade cells in xeno-free, feeder-free culture, by utilizing methods of growing the cells in suspension. Cellect has a unique technology that can functionally select stem cells based on their sensitivity to apoptosis.

Interview with Dr. Askenase – Role of MSC-Derived Exosomes in Healing the Injured Spinal Cord

Dr. Askenase is an expert in the effector properties of exosomes who is now beginning to study mesenchymal stem cell (MSC)-derived exosomes and their role in regenerative processes. Dr. Askenase’s new unpublished preliminary work is focused on the role of MSC-derived exosomes in healing the injured spinal cord in rats. In this interview, we discuss the growing importance of MSC-derived exosomes, including their advantages and applications, the market potential for exosomes, and companies competing in this emerging market area.

iPSC-derived cardiomyocte therapy

Enrollment Complete for CardioCell’s Phase IIa Chronic Heart Failure Trial Utilizing Ischemia-Tolerant MSCs

CardioCell, LLC, annnounced that it had completed enrollment for its Phase IIa chronic heart failure (HF) clinical trial. The Phase IIa study protocol delivers ischemia-tolerant mesenchymal stem cells (itMSCs) via intravenous infusion to participants with non-ischemic cardiomyopathy. CardioCell’s itMSCs are exclusively licensed from its parent company, Stemedica.

Regulation of the Stem Cell Market is a Tipping Point – Which Way Will It Fall?

The stem cell market has grown increasingly complex over the past few years, especially in the regulatory space. The NIH recently had an overwhelming response for participation in its Part 15 hearing to review draft guidances controlling the regulation of stem cells. The Office of U.S. Senator for Illinois, Mark Kirk, also introduced the REGROW Act in March 2016, which has been exceedingly controversial. Regulation of the stem cell market is at a tipping point, but which direction it will fall?

Update: FDA Reschedules Part 15 Public Hearing for September 12-13 (5 Month Delay)

After the FDA received more than 600 registrations for its Part 15 Hearing to review “Draft Guidances Relating to the Regulation of Human Cells, Tissues or Cellular or Tissue-Based Products,” it cancelled the originally scheduled event. The FDA announced the rescheduled hearing will occur over September 12-13, 2016, at Masur Auditorium on the NIH campus. Two-day format is a substantial improvement over the original one-day format, as is the larger venue size.

Global Strategic Report — “Complete 2015-16 Global Cord Blood Banking Industry Report”

This 204-page report analyzes key metrics that impact the cord blood banking market, including trend rate data for cord blood clinical trials, patents, grants, and scientific publications, as well as rates of cord blood storage and utilization. It identifies investors entering the marketplace and emerging trends that are impacting new regions.  A distinctive feature of the report is a survey of 600+ recent and expectant parents that reveals how to strategically position your products, effectively educate parents, and prioritize your marketing budget. It identifies why parents bank publicly, privately, or not at all.

*Have an important stem cell announcement to share? Email “Info@BioInformant.com” to send it with us.

Rate this post

Filed Under: MSCs, Stem Cells Tagged With: Accellta, CardioCell, Cellect Biomed Ltd., STEMCELL Technologies

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.